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Dictyostelium: a nonpathogenic, soil-dwelling amoeba whose ability to form
multicellular ‘slugs’ has made it a model organism for studying the collective
behaviour of single-celled organisms and chemotaxis using cAMP.
Expression sites: loci found at the telomeres of large and intermediate
chromosomes of Trypanosoma brucei. Polycistronic transcription of VSG and
ESAGs occurs here and is restricted to one expression site at a time.
Phagolysosome: the compartment in phagocytic cells that is the result of
fusion between the phagosome and lysosomes. Protozoan parasites will either
be degraded here or, as is the case for Leishmania spp., may go on to make this
compartment their intracellular niche for replication.
Pseudogenes: genomic DNA sequences related to protein-coding genes but
which have lost their ability to encode proteins due to mutations.
Selectivity ratio: the selectivity ratio for a drug is defined as the ‘IC50 for off-
target enzyme/IC50 for target enzyme’, where the IC50 is the half-maximal
concentration of drug needed to inhibit the enzyme. The higher the ratio, theDespite recent research linking cAMP signalling to
virulence in trypanosomatids and detailed studies of
trypanosomatid adenylyl cyclases (ACs) and phospho-
diesterases (PDEs) since their discoveries 40 years ago,
downstream components of the pathway and their
biological functions have remained remarkably elu-
sive. However, in recent years, significant discoveries
have been made: a role for parasite ACs has been
proposed in cytokinesis, evasion of the host immune
response, and social motility. cAMP phosphodies-
terases PDEB1 and PDEB2 were found to be essential
for survival and virulence of Trypanosoma brucei and,
in Trypanosoma cruzi, PDEC2 was shown to be re-
quired for normal osmoregulation. As we discuss here,
these breakthroughs have led to an ongoing surge in
the development of PDE inhibitors as lead compounds
for trypanocidal drugs.
Trypanosomatids cause a spectrum of globally
important diseases
The trypanosomatids are protozoans of the class Kineto-
plastida, which includes Trypanosoma cruzi, African Try-
panosoma spp., and Leishmania spp.. Subspecies of the
African parasite Trypanosoma brucei (Figure 1) cause
economically important nagana in African cattle as well
as human sleeping sickness, which is fatal without treat-
ment in most cases [1]. Trypanosoma cruzi is the causative
agent of Chagas disease, which can lie dormant for many
years before emerging as a severe disease resulting in
smooth muscle damage and, in some cases, sudden cardiac
death [2]. Leishmania spp. cause a spectrum of diseases,
ranging from a mild cutaneous form [3] to a lethal visceral
form affecting the internal organs [4]. Most of the currently
available drugs cannot be administered orally, require long
courses of treatment, and do not always result in parasite
clearance [1,5,6]. Several of these drugs are associated
with unacceptable levels of toxicity: melarsoprol is the only
drug available for late-stage T. b. rhodesiense infections
and is itself the cause of death due to encephalopathy in1471-4922/
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cyclases.approximately 5% of patients [7]. Despite the high global
health burden caused by trypanosomatids in developing
countries and the inadequacy of current treatments, new
drugs have been slow to emerge [8].
Presence of cAMP pathway components in
trypanosomatids
cAMP is a second messenger signalling molecule conserved
from bacteria to humans and involved in processes as
diverse as chemotaxis in Dictyostelium and olfaction in
mammals [9]. The importance of cAMP signalling in T.
brucei is hinted at by its high number of genome-encoded
ACs, with over 80 genes and pseudogenes (see Glossary)
[10] predicted by genome analysis. It remains a mystery
why T. brucei in particular has evolved to have such a large
number of ACs compared with other trypanosomatids.
Speculation about putative links between the abundance
of AC genes and their functions, such as immune evasion or
resolution of multiple incoming signals, could spark inter-
esting research. Observations made over the past 30 years
correlating cAMP levels with different life-cycle stages
have also pointed towards an important role in develop-
ment [11]. The discovery that dual knockdown of PDEB1
and PDEB2 in T. brucei leads to almost complete inhibition
of parasite growth in mouse models [12] was the firstmore selective the drug is for the target enzyme.
Trans-sialidases: this large family of Trypanosoma cruzi enzymes transfers
alpha(2-3)-linked sialic acid from sialoglycoconjugates on the host cell surface
to an acceptor on the parasite surface, thereby helping to disguise the parasite
with a molecule that the immune system recognises as self.
Tsetse fly: a large fly (genus Glossina) that is found across mid-continental
Africa. It lives on the blood from vertebrate animals, including humans, and is
responsible for transmitting African trypanosomes (T. brucei, Trypanosoma
congolense, and Trypanosoma vivax).
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Figure 1. cAMP signalling in the life cycle of Trypanosoma brucei. (1) Long slender
bloodstream form in the mammalian bloodstream; the position of major
organelles is indicated: flagellum (F), nucleus (N), and kinetoplast (K; contains
mitochondrial DNA). The adenylyl cyclase (AC) expression site-associated gene 4
(ESAG4) has been implicated in modulation of the host innate immune response
[10] and members of the ESAG4 subfamily are important for control of cell division
[19]. (2) Short stumpy bloodstream form, which is pre-adapted to differentiate to
procyclic forms following ingestion by a tsetse fly. (3) Early procyclic
trypomastigote in the tsetse fly midgut. ACs have been implicated in the
regulation of social motility [50]. (4) Late procyclic trypomastigote. (5) Elongated
trypomastigote, which migrates to the proventriculus. Here, a single asymmetric
division produces one long epimastigote, which is thought to decay (not shown)
and one short epimastigote (6), which goes on to colonise the tsetse fly salivary
glands. (7) Epimastigote attached to the salivary gland. (8) Mammalian-infective
metacyclic trypomastigote, which is released from the gland to infect a mammal
during a blood meal. Curved arrows denote stages undergoing proliferative cell
cycles.
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thereby highlighting cAMP effectors as potential therapeu-
tic targets Here, we summarise recent advances in our
knowledge of the role of cAMP signalling in pathogenesis
and where we stand with the ongoing development of drugs
against parasite PDEs.
Characterisation of the expression site-associated gene
4 subfamily of ACs in T. brucei
ACs catalyse the formation of cAMP from ATP. The cata-
lytic domains of class II trypanosomatid cyclases share
homology with mammalian class III cyclases, but there are
several important distinctions in their structure and pro-
posed mode of action [13]. Whereas the mammalian pro-
tein has 12 transmembrane domains, the trypanosomatid
ACs have a single transmembrane domain and function as
dimers [11,13–15], with the recently described exception of374a soluble heme-containing Leishmania major AC, HemAC-
Lm, which catalyses cAMP production in response to oxy-
gen binding (Figure 2) [16]. Mammalian ACs are indirectly
activated by G protein-coupled receptors (GPCRs), which
are eukaryotic transmembrane receptors that interact
with extracellular ligands to activate heterotrimeric G
proteins on the intracellular side of the membrane [17]. Ac-
tivated GTP-bound G proteins diffuse laterally in the
membrane to regulate transmembrane effectors, including
AC. Trypanosomatid ACs have an insertion in the G
protein-binding domain and the trypanosomatid genomes
are thought to contain no heterotrimeric G protein homo-
logues [11]. In contrast to mammalian ACs, the trypano-
somatid ACs have large variable extracellular N-terminal
domains; this feature suggests direct interaction with
extracellular ligands. Despite the intriguing N termini of
these ACs, we have come no further in recent years in
characterising specific ligands that could activate them.
The T. brucei genome contains multiple expression sites
(ESs) for a highly expressed variable surface glycoprotein
(VSG) that are located downstream of small numbers of co-
transcribed genes called expression site-associated genes
(ESAGs) [18]. The genome of T. brucei encodes approxi-
mately 80 AC homologues, some of which are ESAGs
[19]. A functionally redundant subfamily of ESAG4 genes
includes ESAG4 itself and two ESAG4-like genes, which
are non-ES associated [19]. This subfamily is highly
expressed in the proliferative slender bloodstream form
compared with the cell cycle-arrested tsetse-infective
stumpy form of T. brucei (Figure 1) [19]. Inducible RNAi
knockdown of this subfamily leads to cytokinesis defects
with a build up of late cell cycle-stage cells, leading to cell
death and decreased virulence in mice (Figure 2) [19]; this
was the first phenotype to be characterised upon knock-
down of a trypanosomatid AC. Given that VSG is the
dominant surface protein in bloodstream-form parasites
whose knockdown leads to inhibition of cell cycle progres-
sion [20], the authors speculated that the ESAG4 subfami-
ly is involved in sensing aberrant VSG coats as part of a cell
cycle checkpoint [19]. This exciting theory remains to be
tested.
A further study by the same laboratory implicated
ESAG4 in modulation of the host innate immune re-
sponse [10]. ESAG4 catalytic domain inactivation re-
duced total parasite AC activity by 50%, despite the
apparent redundancy of the ESAG4 subfamily seen in
the previous study [10]. These ESAG4 mutants had only
slight cytokinesis defects and showed reduced parasitae-
mia and longer survival of infected mice. This was linked
to a reduction of protein kinase A (PKA) activation in
host phagocytic cells compared with infections with wild
type T. brucei [10]. Reduced PKA activation resulted in
increased tumour necrosis factor (TNF)-a production and
inhibition of parasite growth, suggesting a possible role
for the parasite AC in regulation of host cell responses
[10]. How parasite cAMP or even the transmembrane AC
could be translocated from the phagolysosome to act in
the host cytoplasm was not addressed. Therefore, it is
unclear whether host PKA is activated by cAMP synthe-
sised by ESAG4 or via an indirect, ESAG4-dependent
mechanism.
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Figure 2. An overview of potential drug targets in cAMP signalling pathways in trypanosomatids. Potential drug targets are highlighted as filled circles and colour coded as
follows: pink, protein kinase A (PKA); red, phosphodiesterase (PDE); and dark blue, adenylyl cyclase (AC). (A) A cAMP signalling pathway in Leishmania mediates cellular
adaptation and survival during hypoxia. In Leishmania major promastigotes, knockout of heme-containing AC (HemAC-Lm) under hypoxic conditions leads to increased
cell death [16]. It is unknown whether HemAC-Lm inhibition leads to cell death in mammalian-stage parasites, but it is possible that HemAC-Lm has a role in adaptation to
changes in environmental oxygen in all life-cycle stages by catalysing the production of cAMP, which binds and activates PKA leading to multiple downstream effects. (B)
cAMP signalling components regulate essential processes in Trypanosoma cruzi. Inhibition of PKA in epimastigotes induces cell death [32] and is potentially implicated in
immune evasion in the mammalian host by its interaction with trans-sialidases in trypomastigotes [33]. PKA localises to both the cytosol and plasma membrane in
trypomastigotes. The contractile vacuole complex (CVC) is part of the membranous spongiome network, which is essential for osmoregulation in T. cruzi. Inhibition of
TcrPDEC2, which localises to the spongiome, in epimastigotes leads to dysregulation of the hyposmotic stress response [54], but it is unknown whether TcrPDEC2 also
regulates this process in mammalian-stage parasites. (C) PDEB1 and 2 localise to the paraflagellar rod (PFR) and, when simultaneously knocked down, cell death occurs in
vitro and the parasites are avirulent in mice [12]. ESAG4 subfamily members are flagellar membrane-localised ACs that are highly expressed in bloodstream-form parasites.
When the subfamily is simultaneously knocked down, cytokinesis defects occur, leading to cell death and the parasites have attenuated virulence in a mouse model [19].
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Over 30 years of research have linked cAMP levels to
differentiation through the life cycle (reviewed in [21]);
for example, in the T. brucei slender bloodstream form,
intracellular cAMP levels are five times higher than in the
stumpy form [21,22]. Changes in cellular cAMP level with
life-cycle stage have also been observed in T. cruzi [23,24]
and Leishmania spp. [16]. These observations were backed
up by the fact that the membrane-permeable cAMP ana-
logue 8-(4-chlorophenylthio)-cAMP could induce slender to
stumpy differentiation in T. brucei [25]. It is now known
that this signal is not cAMP but the products of cAMP
hydrolysis [26]. This finding does not necessarily rule out
the involvement of canonical cAMP signalling components,
because ACs may be necessary for initial cAMP production
before hydrolysis if cAMP is the initial signal in vivo. In
addition, the cAMP effector PKA regulatory subunit (PKA-
R) was linked to slender form growth arrest in an RNAiscreen [27]. The identification of PKA-R is surprising
because T. brucei PKA is thought to be cGMP dependent,
although the presence of cGMP in T. brucei has not yet
been confirmed [28]; it is possible that PKA-R is involved in
rebalancing purine levels.
cAMP signalling proteins are important for host–
parasite interaction
PKA is a well-known effector of cAMP in mammalian cells,
where it phosphorylates a large number of downstream
targets to allosterically modulate their activity and induce
a cellular response to elevated cAMP levels [29]. A PKA
homologue is present in trypanosomatids, although it does
not appear to be cAMP dependent in T. brucei, where it may
have undergone divergent evolution [11,28]. However, PKA
is cAMP dependent in L. major, where PKA activity was
shown to positively correlate with cAMP levels produced by
the oxygen-dependent AC HemAC-Lm [16,30]. Knockout of375
Review Trends in Parasitology August 2015, Vol. 31, No. 8HemAC-Lm under hypoxic conditions resulted in increased
cell death [16], suggesting a role for this AC in the survival of
the parasite in response to changes in environmental oxygen
concentration during its life cycle. Trypanosoma cruzi also
contains a cAMP-dependent PKA and its inhibition by a
genetically encoded PKA inhibitor induced cell death in
epimastigotes (Figure 2) [31,32]. Downstream effectors in
T. cruzi remained unknown until Bao et al. performed a
yeast two-hybrid screen for TcrPKA catalytic subunit bind-
ing partners (Figure 2) [32,33]. They identified members of
the trans-sialidase superfamily, which are important for
evasion of the complement-mediated immune system in
the human host as well as attachment to, and invasion of,
host cells. Validation of this association by other means
would be valuable to exclude the possibility of false positives
from the yeast two-hybrid screen.
The first downstream cAMP effectors in T. brucei were
found by Gould et al. in a RNAi screen for PDE inhibition
resistance [34]. The putative genes identified were desig-
nated cAMP response proteins 1–4 (CARP1–4). CARP2
and CARP4 are found in the flagellar proteome [35],
highlighting the fact that many components of the cAMP
signalling pathway, including ACs, PDEs and PKA, are
flagellar localised [12,36–38]. The flagellum is an essential
organelle and potential drug target, which may serve as a
signalling centre for some cAMP-dependent processes [39–
41]. CARP1 has homology with mammalian cyclic nucleo-
tide-gated ion channels (CNGs), which are well known as
cAMP effectors in mammals [42,43]. In another protist,
Dictyostelium, a mitogen-activated protein kinase (MAPK)
phosphatase conserved in trypanosomatids is involved in
the response to cAMP as a chemoattractant [44]. The
connection of cAMP and MAPK signalling with prolifera-
tion is well known in mammalian cells [45]. In T. cruzi,
MAPKs have been found to interact with PKA and PDEs in
the flagellum [46]; thus, it seems likely that there is MAPK/
cAMP signalling crosstalk. Could this be linked with che-
moattraction, as in Dictyostelium? This process is poorly
understood in trypanosomatids, but is thought to be nec-
essary to mediate host–vector transfer and navigation in
the insect vector [47].
Swarming behaviour reminiscent of bacteria on a semi-
solid agarose surface is an intriguing and rather enigmatic
characteristic of early procyclic T. brucei [48]. Two inde-
pendent labs have recently proposed this so-called ‘social
motility’ to be important in the colonisation of the tsetse
midgut (Figure 1) [49,50] and, therefore, it could have an
important role in navigation through the fly. ACs were
identified as possible candidates for regulation of social
motility based on reciprocal upregulation of expression of
AC330 (Tb927.5.285b) and AC320 (Tb927.5.320) in early
and late procyclics, respectively [49]. Subsequently, RNAi
knockdown of AC6 (Tb927.7.7470) or dual knockdown of
AC1 (Tb927.11.17040) and AC2 (Tb927.10.16190) was
found to produce a hypersocial phenotype [50], defined
by an increase in the number of swarming groups, impli-
cating these ACs as negative regulators of social motility.
This work adds T. brucei to the list of microorganisms that
use cyclic nucleotide signalling to collectively navigate
their environment [51,52]. Interestingly, AC6 has a flagel-
lar tip localisation and, when knocked down, there is no376significant reduction in the gross level of cAMP in the
population despite the hypersocial phenotype. Thus, in
this case, it is modulation of the local concentration of
cAMP rather than the total level in the whole cell that
regulates social motility; this hints towards the emerging
role of cAMP signalling compartments in the regulation of
the cellular response [50].
PDEs are potential drugs targets
PDEs catalyse the hydrolysis of cAMP to AMP, leading to
negative regulation of cAMP signalling. There are four
groups of trypanosomatid cAMP PDE (PDEA–D), which
are structurally similar to human PDEs [11]. Each group is
represented by one or two protein members across the
trypanosomatids. Despite their promise as drug targets,
the exact functions of trypanosomatid PDEs remain under-
researched and most of our knowledge is based on their
subcellular localisation [39]. PDEB1 and PDEB2 knock-
down in T. brucei was found to produce multiflagellated,
multinuclear cells that eventually undergo lysis after 42 h
and that are essentially avirulent in mouse models
(Figure 2) [12]. A clue to the underlying mechanisms of
this phenotype may lie in the fact that PDEB1 and PDEB2
have overlapping subcellular localisations: both localise to
the paraflagellar rod (PFR), a kinetoplastid-specific struc-
ture that lies alongside the flagellar axoneme (Figure 2)
and that is essential for normal motility and viability in the
mammalian host [35,53]; PDEB2 also has an additional
cytoplasmic localisation [12,39].
Trypanosoma cruzi PDEC2 (TcrPDEC2) was found to
localise to the contractile vacuole complex (CVC) via its
phosphatidylinositol (3,4,5)-trisphosphate-binding FYVE
domain [54,55], which is essential for both localisation
and activity. The CVC is an essential organelle for T. cruzi
virulence that takes up osmotically active metabolites in
response to hyposmotic stress, leading to an influx of water
that is later secreted through the flagellar pocket
[56]. TcrPDEC2 inhibition led to dysregulation of the
osmotic stress response (Figure 2) [54]. The study of T.
brucei PDEB1 and PDEB2 dual knockdowns in a mouse
model provides important proof of principle that dysregu-
lation of cAMP signalling can decrease virulence in vivo. In
addition, PDEs are required for the normal function of the
T. cruzi CVC, which is needed for virulence. Taken togeth-
er, these studies suggest that PDEs are virulence factors
and, therefore, promising drug targets.
Development of drugs against parasite PDEs
PDEBs have been found to be essential proteins in viru-
lence and cell survival [12]; therefore, most drug discovery
effort has gone into targeting this group, and TcrPDECs
[57] to a lesser extent. The wealth of research in drug
development against human PDEs (hPDEs) provides a
valuable source of lead compounds and research techni-
ques, and the success of licensed hPDE inhibitors in the
clinic [58,59] underlines their promise as drug targets
Thus, the field has focussed on altering the specificity of
existing hPDE inhibitors and drugs to target trypanoso-
matid PDEs instead of following the classical drug discov-
ery approach of developing compounds against a unique
target in the pathogen. The fact that there are now over
Box 1. Outstanding questions
 What are the extracellular signals that activate trypanosomatid
ACs? Are there specific ligands for the variable extracellular
domains of different ACs?
 Why is there such a large repertoire of ACs in Trypanosoma
brucei ?
 What is the mechanistic link between T. brucei AC activity and
cytokinesis? Is cytokinesis failure a direct or indirect consequence
of the ablation of ESAG4 and are aberrations in the VSG coat
sensed through ESAG4?
 What is the mechanistic link between T. brucei AC activity and
‘social motility’? Do specific flagellar ACs modulate the beat
pattern of the flagellum, impacting on directional motility? Can
factors produced by one trypanosome activate ACs in another?
 Is PKA in cells of infected animals activated directly by ESAG4-
generated cAMP? How might T. brucei-generated cAMP or even
the transmembrane AC itself be translocated from the phagolyso-
some to act in cells of the infected animal to modulate immune
responses?
 If the T. brucei PKA homologue is not activated by cAMP, does
another protein fulfil its function as a master regulator of
downstream effectors of cAMP signalling?
 Will targeting the P-pocket of trypanosomatid PDEs produce drug
candidates with high enough selectivity for parasite versus
human PDEs to be safe and effective drugs?
Review Trends in Parasitology August 2015, Vol. 31, No. 850 published inhibitors for TbrPDEB1 alone suggests
that this unconventional approach has been fruitful [60],
although it remains to be seen whether good inhibitors will
make good drugs. It should be noted that, to produce a lethal
phenotype, both PDEB1 and PDEB2 must be inhibited, and
that, due to their similar amino acid sequences, it is pre-
dicted that an inhibitor designed against one will inhibit
both. The high affinity inhibitor CpdA was developed
against TbrPDEB1 [61] and induces the same phenotype
that TbrPDEB1/2 knockdown produces. Significantly, pre-
incubation of T. brucei with CpdA led to greatly reduced
infectivity upon injection into mice [61].
Crystal structures of TcrPDEC [62], TbrPDEB1 [60],
and L. major LmjPDEB1 [63] have now been solved and
will push forward the discovery of new drugs to fit and
inhibit catalytic domains and parasite-specific features. All
of these structures confirm the presence of a parasite-
specific pocket (P-pocket) next to the active site, which
forms a pore through the protein between residues Gln874
and Tyr845. In human PDEs, the pore is gated by two large
residues, which are replaced with much smaller residues in
the P-pocket. The presence of such a parasite-specific
feature is key to the success of drug discovery attempts
that target proteins with close human homologues. The
TbrPDEB1 P-pocket has been targeted by carrying out
fragment growing of existing hPDE-specific compounds
into the P-pocket [64] to try and improve the selectivity
ratio of these compounds. This technique resulted in com-
pound 20b, which inhibited TbrPDEB1 at nanomolar con-
centrations. The compound has a selectivity ratio for hPDE
of four, which would be unacceptable in a drug [65], but it is
already an improvement on previous inhibitors [64]. In-
deed, P-pocket binding was found to be an important
selectivity driver in an in silico screen of a compound
library using P-pocket interactions and restrictions im-
posed by known TbrPDEB1 inhibitors as guidelines
[60]. This study found six new TbrPDEB1 inhibitors with
the lowest selectivity ratio for hPDE being 0.4. Orrling
et al. suggest that a selectivity ratio of 10–100 for the
parasite enzyme would be desirable in future drug discov-
ery attempts [64]; therefore, these new inhibitors could be
good candidates for optimisation. Factors other than selec-
tivity ratio affecting the safety of potential drugs include
tolerance of human cells to PDE inhibition and differential
effects on specific tissues in the body.
Concluding remarks
Characterisation of ligands for the extracellular domain of
trypanosomatid ACs is likely to be crucial in our under-
standing of host–parasite interactions and should be a
priority (Box 1). For the first time, functions have been
assigned to ACs themselves; the possible role of ESAG4 in
modulation of the host immune response illustrates the
importance of cAMP signalling in host–parasite interac-
tions. Understanding progression through the complex life
cycles of trypanosomatid parasites is crucial to enable
targeted therapeutic intervention. The first in-depth study
of a specific role for cAMP in T. brucei differentiation has
dispelled the historical view that canonical cAMP signal-
ling is involved. This finding should lead the field to
question the involvement of canonical cAMP signallingin other life-cycle switches in trypanosomatids. The study
of downstream effectors of cAMP signalling has identified
proteins that are crucial for survival in the host, although
these represent only a fraction of the total protein compo-
nent that is likely to be cAMP regulated. The largest body
of work in this area has been in drug development. The
relatively fast development of many trypanosomatid PDE
inhibitors illustrates the value of targeting a parasite
protein with homologues that have already been exploited
in the treatment of human disorders. Using an existing
pool of lead compounds has significantly reduced the re-
search time required for the initial stages of drug discov-
ery, and inhibitors developed over the past couple of years
are promising candidates for optimisation. However, we
are still far from producing drug candidates due to the
inherent problem of achieving high selectivity for the
parasite protein using this approach. The drugs with the
highest selectivity ratio for the parasite enzyme so far have
been produced by targeting parasite-specific features of
PDEs, as revealed by recent crystal structure data, and
future work should continue this approach.
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